Eli Lilly & Co. urged doctors to prescribe Zyprexa for elderly patients with dementia, an unapproved use for the antipsychotic, even though the drugmaker had evidence the medicine didn’t work for such patients, according to unsealed internal company documents.
In 1999, four years after Lilly sent study results to the U.S. Food and Drug Administration showing Zyprexa didn’t alleviate dementia symptoms in older patients, it began marketing the drug to those very people, according to documents unsealed in insurer suits against the company for overpayment.
Lilly Sold Drug for Dementia Knowing It Didn’t Help, Files Show
Toothpaste can be widely contaminated with lead and other dangerous heavy metals, new research shows.
Most of...
CT scans diagnose afflictions from tumors to kidney stones to life-threatening diseases and injuries, such as...
